BioSpace News Archive

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its third quarter 2019 financial results on Wednesday, October 30, 2019.

BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that Jennifer Chao has been appointed chairperson of its board of directors,

EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced that three abstracts highlighting its Ancer™ platform have been accepted for presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting from November 6-10, 2019 in National Harbor, Maryland.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2019 on Thursday, October 31, 2019,

Douglas Bain will take over as the head of the company’s growing technology sector

Cyclo Therapeutics, Inc. announced that Sharon H. Hrynkow, Ph.D., its Chief Scientific Officer and Senior Vice President for Medical Affairs, has been appointed to the President’s Council of Advisors on Science and Technology On October 22, President Donald J. Trump signed an executive order re-chartering PCAST and announced the first seven members, including Dr. Hrynkow.

XBiotech Inc. announced that the first patient was enrolled in its randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating bermekimab in patients with moderate to severe Hidradenitis Suppurativa The multi-center, international study will enroll approximately 150 patients into three arms: two bermekimab dosing regimens versus a placebo arm over sixteen weeks of therapy.

RAPT Therapeutics, Inc. reported the initiation of its first-in-human Phase 1 clinical trial for RPT193, an orally-administered small molecule CCR4 antagonist that is designed to selectively inhibit the migration of type 2 T helper cells, or Th2 cells, into allergically-inflamed tissues.

Abacus Health Products, Inc. announced that it has received approval from the Depository Trust Company to make the Company’s subordinate voting shares eligible to be electronically cleared and settled through DTC.

Breast Cancer Awareness Month may be winding down, but Patricia Levett’s battle against metastatic breast cancer continues. This week, the 48-year-old grandmother from Clayton, North Carolina, will embark on her 27th Miracle Flight to the ongoing medical treatment that’s saving her life.